黑色素瘤中的双重免疫检查点抑制与PD-L1表达：尚无定论。
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out.
作者信息
Schmitt Andreas Michael, Larkin James, Patel Sapna P
机构信息
Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
出版信息
J Clin Oncol. 2025 Jan 10;43(2):122-124. doi: 10.1200/JCO-24-01572. Epub 2024 Oct 7.
PMID:39374477
Abstract
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
摘要
本评论讨论了使用程序性死亡受体配体1（PD-L1）作为生物标志物来指导转移性黑色素瘤的治疗决策。
Zotero 插件